Who Owns Ultragenyx Company?

Ultragenyx Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Ultragenyx?

Understanding a company's ownership structure is crucial for investors and analysts alike. Ultragenyx, a biopharmaceutical innovator, presents a compelling case study in how ownership evolves, especially after its 2014 IPO. Exploring Ultragenyx SWOT Analysis can offer further insights into its strategic positioning.

Ultragenyx's journey from a privately-funded startup to a publicly-traded entity on Nasdaq ('RARE') offers valuable lessons. Discovering who owns Ultragenyx, from its founders and early backers to its current major shareholders, is key to understanding its direction. This deep dive into Ultragenyx ownership will also cover the influence of its Board of Directors and the role of institutional investors.

The company, Ultragenyx, was founded in 2010. The founder, Emil D. Kakkis, M.D., Ph.D., a key figure in the rare disease space, established the company with a clear focus on addressing unmet medical needs.

Early funding rounds were crucial for Ultragenyx. They secured significant capital to advance their research and development programs. This early financial backing was essential in shaping the company's trajectory.

The initial venture funding totaled over $120 million before the company went public in 2014. This early investment supported the company's strategic direction, particularly in the rare disease market. Knowing the Ultragenyx ownership structure is important for investors.

Founder's Vision

Emil D. Kakkis, with his background in genetic diseases, drove the company's focus. His experience in enzyme replacement therapy and previous roles significantly influenced Ultragenyx's early strategy.

Early Funding

The Series A round in 2011 raised approximately $45 million. This was followed by a Series B round. These early investments were crucial for fueling research.

Strategic Direction

The focus on rare diseases from the start shaped the company's direction. Dr. Kakkis's vision and the allocation of resources were key. This early strategic focus remains a core part of the company.

Ownership Distribution

Early investors and the founding team received a distribution of ownership. Specific equity splits aren't publicly detailed. The early venture funding indicates a significant distribution.

Public Offering

Ultragenyx went public in 2014. This marked a major shift in the company's ownership structure. The IPO provided access to further capital.

Rare Disease Focus

The company's commitment to rare diseases has been consistent. This focus has guided its research and development efforts. Ultragenyx continues to target unmet needs in this area.

Key Takeaways

Understanding the early history of Ultragenyx is important for investors. The company's foundation, built on the vision of Dr. Kakkis and early funding, set the stage for its future. For more details, consider reading about the Growth Strategy of Ultragenyx .

• Emil D. Kakkis founded Ultragenyx in 2010.
• Early funding rounds totaled over $120 million before the IPO.
• The focus on rare diseases shaped the company's strategic direction.
• The company's IPO occurred in 2014.

Ultragenyx SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The journey of Ultragenyx began as a privately funded entity. This changed on January 31, 2014, when it became a publicly traded company. This transition occurred through an Initial Public Offering (IPO) on The NASDAQ Global Select Market, using the ticker symbol 'RARE.' The IPO involved the sale of 5,760,369 shares at $21.00 each, which raised $126 million.

The ownership structure of Ultragenyx has evolved significantly since its IPO. A key event impacting the company’s equity was the underwritten public offering in June 2024. This offering generated approximately $381.0 million in net proceeds through the sale of common stock and pre-funded warrants. This event further illustrates shifts in equity allocation and capital management within the company. Understanding the Target Market of Ultragenyx can also provide insights into the company's strategic direction.

As of May 2025, Ultragenyx's ownership is heavily influenced by institutional investors. Major stakeholders include Vanguard Group Inc., BlackRock, Inc., Sands Capital Management, LLC, T. Rowe Price Associates Inc./MD, and State Street Corp. The substantial institutional ownership gives these large financial firms significant voting power, which influences the company's governance and strategic decisions. For the year 2024, Ultragenyx reported total revenue of $560 million, surpassing its initial guidance. Projections for 2025 estimate total revenue between $640 million and $670 million.

Key Takeaways on Ultragenyx Ownership

Ultragenyx is predominantly owned by institutional investors, with a small percentage held by insiders and the public. The IPO in 2014 marked a significant shift, transitioning the company from private to public ownership. Major institutional holders like Vanguard and BlackRock have a substantial influence on the company's direction.

• Institutional investors hold the majority of Ultragenyx stock.
• The IPO was a pivotal moment in the company's financial history.
• Key institutional holders significantly influence company decisions.
• Revenue projections for 2025 are between $640 million and $670 million.

Ultragenyx PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of the latest reports, the board of directors at Ultragenyx provides strategic direction for its focus on rare genetic diseases. Key figures include Emil D. Kakkis, M.D., Ph.D., who is the Founder, President, and Chief Executive Officer, and Daniel G. Welch, who serves as Chairperson. Other board members include Deborah Dunsire, M.D., Matthew K. Fust, Michael Narachi, Amrit Ray, M.D., M.B.A., Corsee D. Sanders, Ph.D., and Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil. This team comprises a mix of founders, biotechnology executives, and physicians, showcasing a diverse range of expertise. Karah Parschauer, Chief Legal Officer & Executive Vice President at Ultragenyx, was elected to the Alliance for Regenerative Medicine's 2025 Board of Directors in October 2024, demonstrating leadership within the industry.

The composition of the board reflects a commitment to both scientific and business acumen, vital for navigating the complexities of the biotechnology sector. The board's collective experience supports Ultragenyx's mission to develop and commercialize therapies for rare diseases. This includes overseeing financial performance and strategic initiatives to advance the company's pipeline of treatments. Understanding the Competitors Landscape of Ultragenyx is also essential in this context.

Regarding voting structure, each holder of Ultragenyx common stock is entitled to one vote per share on all matters submitted to a vote of stockholders. Generally, directors are elected by a plurality of the votes cast, while other matters require approval by a majority of the votes cast. Stockholders do not have cumulative voting rights. There is no public information suggesting dual-class shares or special voting rights that would grant outsized control to specific entities. Proxy statements, such as the one filed in March 2025 for the May 2025 Annual Meeting, outline the election of directors and other proposals, which are approved by the Board and recommended for stockholder vote. This structure ensures that all shareholders have a proportional say in the company's governance.

Key Takeaways on Ultragenyx Ownership

The Board of Directors at Ultragenyx is composed of experienced individuals from the biotechnology and medical fields.

• Emil D. Kakkis, M.D., Ph.D. is the Founder, President, and CEO.
• Daniel G. Welch serves as the Chairperson.
• Each share of common stock has one vote.
• Directors are elected by a plurality of votes.

Ultragenyx Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, significant developments have shaped the ownership of Ultragenyx. In June 2024, the company completed an underwritten public offering, raising a net of $$381.0 million through the sale of common stock and pre-funded warrants. This capital raise, along with the Sales Agreement for an 'at-the-market' (ATM) offering of up to $$350.0 million in common stock, reflects strategic efforts to fund the company's growth. These actions can influence the dynamics of Ultragenyx ownership.

Recent data indicates shifts in the composition of Ultragenyx's shareholders. As of May 2025, institutional investors held approximately 97.43% of Ultragenyx's stock, up from 94.95% in April 2025. Insider holdings saw a slight increase from 2.88% in April 2025 to 2.95% in May 2025. Mutual funds' holdings saw a slight decrease from 65.06% in April 2025 to 65.05% in May 2025. These trends highlight the increasing influence of institutional investors. Understanding Growth Strategy of Ultragenyx provides insights into the company's future, which can impact its ownership.

Ultragenyx's financial performance also offers context. The company anticipates total revenue between $640 million and $670 million for 2025, a projected growth of 14-20% compared to 2024. In the first quarter of 2025, Ultragenyx reported a net loss of $151 million, compared to $171 million for the same period in 2024. As of March 31, 2025, cash, cash equivalents, and marketable debt securities stood at $563 million. These figures are crucial for understanding the company's financial health and how it might affect Ultragenyx ownership and Ultragenyx investors.

Institutional Ownership

Institutional investors hold a significant portion of Ultragenyx stock, indicating a strong vote of confidence from major financial players. This high level of institutional ownership can provide stability and influence the company's strategic direction.

Financial Performance

Ultragenyx's projected revenue growth for 2025 and its cash position are key indicators of its financial health. These figures are essential for assessing the company's ability to fund its operations and future growth initiatives, influencing its ownership structure.

Ultragenyx Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs